Precigen submits BLA for PRGN-2012 gene therapy targeting RRP, a rare and life-threatening condition with no cure.
The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product.
Verastem's pipeline's emphasis is on RAS/MAPK-driven tumors, so the FDA's ruling might have a major influence on their ...
Lenacapavir has shown high efficacy in managing multidrug-resistant cases offering hope to patients with limited alternatives A significant breakthrough in treating the Human Immunodeficiency Virus HI ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...
Hosted on MSN3d
Axsome Therapeutics Stock Tumbles As Alzheimer's Studies Reveal Mixed Results: Retail Sentiment Remains BullishShares of Axsome Therapeutics (AXSM) fell over 11% in Monday morning trade after it posted mixed results of its Alzheimer’s ...
ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse)ACCORD-2 Phase 3 ...
The latest update is out from Galera Therapeutics ( (GRTX) ).
Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...
DOVBLERON® was approved by China’s National Medical Products Administration (NMPA): 1) for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC who have previously ...
Hyderabad: Researchers at the National Institute of Nutrition (NIN) have secured a patent for an innovative menopause care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback